Expert Columns, IPO - News, Tatva Chintan Pharma Chem, Click Here

Of the 28 initial public offerings in India in 2021, Tatva Chintan Pharma Chem’s was subscribed 180 times, the second-highest level, behind MTAR Technologies, which was subscribed 200 times.

Here’s why the Tatva Chintan IPO was so attractive:

IPO mania

Popular IPOs are often oversubscribed because traders and investors want to make listing gains. The premium of Tatva Chintan shares in the grey market was a hefty Rs 770 on July 20, the last day of the IPO, an indicator of why there was such an overwhelming response from investors.

Each share was offered in a price band of Rs 1,073 to Rs 1,083, with a minimum order quantity of 13 shares.

Superior business model

Tatva Chintan is the only commercial manufacturer of structure-directing agents for zeolites in India. It is also the second-largest such company globally, according to F&S Report.

Zeolites have varied applications, including as catalysts and adsorbents. When combined with metals such as copper and iron, they are active for selective catalytic reduction, a way of emission control in automotive applications.

The company is one of the leading global producers of an entire range of phase transfer catalysts.

It has strong customer relationships with companies such as Merck, Bayer AG, Asian Paints, Ipox Chemicals KFT, Laurus Labs, Tosoh Asia, SRF and Navin Fluorine.

The company’s products have applications in green chemistry, which is relevant given the growing focus on sustainable technologies and solutions.

Healthy financials

Tatva Chintan’s revenue, earnings before interest, tax, depreciation and amortisation, and profit after tax increased at a compounded annual growth rate of about 21 percent, 39 percent, and 60 percent, respectively over FY19-21, with a 499 bps margin expansion. Return ratios seem healthy, with FY21 return on equity and return on capital employed at 31 percent and 27 percent, respectively, providing confidence to investors.

To Know All IPO Related News, Click Here

Our View

Given the wide application of its products, Tatva Chintan serves customers across various industries and geographies, providing diversification benefits. A high-quality product portfolio, strong R&D capabilities, strategically located manufacturing facilities and focus on green chemistry processes bode well for the company. A stable financial performance and better growth opportunities provide visibility for the long term. Considering all these factors, we rated the IPO ‘subscribe’ for the long term.

Expert Columns, IPO - News, Tatva Chintan Pharma Chem, Click Here

Disclaimer: The views and investment tips expressed by investment expert on Moneycontrol.com are his own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.


Japan travel news, japan travel guides, japan holiday destinations and japan reviews

LATEST NEWS

NEWS RELATED

Tatva Chintan IPO shares trade at more than 100% premium in grey market ahead of listing

Specialty chemical company Tatva Chintan Pharma Chem shares traded at more than 100 percent premium in the grey market on July 27, ahead of listing later this week. The stellar IPO subscription, leading position in manufacturing of structure-directing agents for zeolites in India, healthy financials and return ratios, and high…

Read more: Tatva Chintan IPO shares trade at more than 100% premium in grey market ahead of listing

A wealth manager's perspective on how HNIs invest in IPOs

Global equity markets have bounced back strongly over the last 15 months following the sharp sell-off in February-March 2020. The rally has been largely fuelled by excessive liquidity resulting from the monetary and fiscal stimulus measures announced by central banks and governments across the world. The rally has also been…

Read more: A wealth manager's perspective on how HNIs invest in IPOs

Tatva Chintan IPO share allotment: Here's how to check your application status

The specialty chemicals company Tatva Chintan Pharma Chem‘s Rs 500-crore public issue received overwhelming response from investors as it was oversubscribed by 180.36 times during July 16-20, the second highest subscription in 2021 after MTAR Technologies. Non-institutional investors put in bids 512.22 times their reserved portion, while the portion set…

Read more: Tatva Chintan IPO share allotment: Here's how to check your application status

ESAF Small Finance Bank files DRHP, to raise Rs 998 crore via IPO

ESAF Small Finance Bank has filed the draft red herring prospectus (DRHP) with the capital market regulator Sebi to raise funds via an initial public offering. The company is planning to raise Rs 997.78 crore through its public issue which consists of a fresh issue of Rs 800 crore and…

Read more: ESAF Small Finance Bank files DRHP, to raise Rs 998 crore via IPO

Paytm looking to launch Rs 16,600-crore IPO by October

Representative image Digital payments and financial services firm Paytm wants to hit the market with its Rs 16,600 crore IPO at the earliest and very likely by October, sources said on Monday. The company had filed draft papers for its initial share sale with the market regulator SEBI on July…

Read more: Paytm looking to launch Rs 16,600-crore IPO by October

Glenmark Life Sciences mobilises Rs 454 crore from anchor investors ahead of IPO

Glenmark Life Sciences on Monday said it has raised Rs 454 crore from anchor investors ahead of its initial share sale, which opens for public subscription on Tuesday. The company has decided to allocate 63,06,660 equity shares to 19 anchor investors at Rs 720 a share, aggregating to Rs 454…

Read more: Glenmark Life Sciences mobilises Rs 454 crore from anchor investors ahead of IPO

Aptus Value Housing gets SEBI approval for up to Rs 3,000 crore IPO

Representational image Aptus Value Housing Finance has received market regulator Securities and Exchange Board of India (SEBI)’s nod for the initial public offering (IPO). The housing finance company had filed its draft red herring prospectus (DRHP) with SEBI on May 14, 2021. Aptus Value Housing Finance,which has a strong capital…

Read more: Aptus Value Housing gets SEBI approval for up to Rs 3,000 crore IPO

IPO Buzz | Carwale owner CarTrade Tech gets SEBI approval for Rs 2,000 crore public listing

Representative image Online auto classifieds platform CarTrade Tech has received the regulatory approval from Securities and Exchange Board of India (SEBI) to float Rs 2,000 crore via the initial public offering (IPO) route. “The issue is a complete offer for sale of 12,354,811 equity shares by Investor and Other Selling…

Read more: IPO Buzz | Carwale owner CarTrade Tech gets SEBI approval for Rs 2,000 crore public listing

IPO party continues as six more firms get SEBI's go-ahead; here're the details

Zomato IPO sets up a new role model for Indian startups

Tatva Chintan IPO share allotment expected today, check your application status here

Exclusive | KFC, Pizza Hut & Costa Coffee Operator Devyani International May Launch IPO On 4th August; 3rd QSR Listing Post Burger King & Barbeque Nation

Is Zomato’s bumper listing making way for upcoming IPOs?

What caused a bumper rally in Zomato stock on debut?

Here are key determinants that govern IPO subscriptions

Zomato IPO: Early investor Sequoia talks about the food delivery giant’s origins and X-factor

OTHER NEWS